Adaptimmune commences synovial sarcoma trial
The company expects to recruit around 10 patients in the trial with an aim to establish the response rate to the therapy. The trial is intended to evaluate
BioMarin Pharmaceutical and n-Lorem Foundation have entered an early-stage research collaboration and exclusive global licence agreement to develop an investigational antisense oligonucleotide (ASO) therapy for ReNU syndrome.